Skip to main content
AmigoFish

Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher

From Pharmaceutical Executive · · 2 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.

Back to Pharmaceutical Executive · Report a problem